PMV Pharmaceuticals, Inc.

PMVP • Biotechnology

$1.29

▲ +0.05 (+4.03%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$68.87M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0.01Healthy liquidity · 10.09Weak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 16, 2026, 12:11 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$1.29

Change4.03%

Shares Out53.39M

Market Cap$68.87M

Enterprise Value$-10.34M

52W Range1.02 - 1.88

Beta1.35

P/E-0.92

P/B0.96

P/FCF-0.97

EV/EBITDA0.13

EV/FCF0.15

Price$1.29

Change4.03%

Shares Out53.39M

Market Cap$68.87M

Enterprise Value$-10.34M

52W Range1.02 - 1.88

Beta1.35

P/E-0.92

P/B0.96

P/FCF-0.97

EV/EBITDA0.13

EV/FCF0.15

Earnings Yield-109.22%

FCF Yield-103.50%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.01

Current Ratio10.09

Quick Ratio10.09

Target$5.00

Target Upside287.60%

Target Median$5.00

Target Range5.00 - 5.00

Volume189.81K

Avg Volume357.06K

EPS Surprise0.07

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

50/100

Price Attractiveness

Cheap or expensive today

95/100

Why this score▼

Manageable debt level · 0.01Healthy liquidity · 10.09Weak profitability

Analyst view

Analyst sentiment and price target

PMVP

Analyst sentiment

Based on 4 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Price Target

2026-08-16

Low

$5.00

Mean

$5.00

Median

$5.00

High

$5.00

Company Overview

IPO: 9/25/2020

Industry: Biotechnology

P/B i: 0.96

Debt / Equity i: 0.01

Operating Margin: 0.00%

Net Margin: 0.00%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.01

Current Ratio: 10.09

Quick Ratio: 10.09

Status: Good

Insider Transactions

Recent executive and insider activity

⚠ 3 high-volume insider sells detected

BAUM CHARLES M

Transaction: 06/04/2026

BUY

Change

+42,000

Price

$1.19

Filing

06/05/2026

Type

BUY

FLOWERS KIRSTEN

Transaction: 06/04/2026

BUY

Change

+42,000

Price

$1.19

Filing

06/05/2026

Type

BUY

Gallagher Carol Giltner

Transaction: 06/04/2026

SELL

Change

-42,000

Price

$1.19

Filing

06/05/2026

Type

SELL

Insider	Type	Change	Price	Transaction	Filing
BAUM CHARLES M	BUY	+42,000	$1.19	06/04/2026	06/05/2026
FLOWERS KIRSTEN	BUY	+42,000	$1.19	06/04/2026	06/05/2026
Gallagher Carol Giltner	SELL	-42,000	$1.19	06/04/2026	06/05/2026
LEVINE ARNOLD J	BUY	+42,000	$1.19	06/04/2026	06/05/2026
Stelzer Laurie	BUY	+42,000	$1.19	06/04/2026	06/05/2026
Mack David Henry	BUY	+744,960	$1.53	03/05/2026	03/09/2026
Jalota Deepika	BUY	+303,310	$1.53	03/05/2026	03/09/2026
Ticktin Robert	BUY	+319,270	$1.53	03/05/2026	03/09/2026
Carulli Michael	BUY	+240,000	$1.53	03/05/2026	03/09/2026
Mack David Henry	SELL	-220,643	$1.37	10/27/2025	10/29/2025
Mack David Henry	BUY	+220,643	$1.37	10/27/2025	10/29/2025
ORBIMED ADVISORS LLC	SELL	-1,000,000	$1.52	10/23/2025	10/27/2025
ORBIMED ADVISORS LLC	SELL	-500,000	$1.80	09/10/2025	09/12/2025
Mack David Henry	SELL	-58,411	$1.06	07/01/2025	07/03/2025
Carulli Michael	SELL	-28,249	$1.06	07/01/2025	07/03/2025
Jalota Deepika	SELL	-33,065	$1.06	07/01/2025	07/03/2025
Ticktin Robert	SELL	-23,151	$1.06	07/01/2025	07/03/2025
BAUM CHARLES M	BUY	+33,500	$0.95	06/05/2025	06/09/2025
FLOWERS KIRSTEN	BUY	+33,500	$0.95	06/05/2025	06/09/2025
Gallagher Carol Giltner	SELL	-33,500	$0.95	06/05/2025	06/09/2025

About the Company

PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.

Source - link

Peers

ACRV ATYR BMEA CBUS IMUX LITS RLMD RPTX TCRX VXRT

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today the pricing of an underwritten public offering consisting of (i) 22,055,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 19,900,000 shares of its common stock, and (ii) accompanying warrants to purchase an aggregate of 41,955,000 shares of common stock. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock for each share of common stock or pre-funded warrant sold. The accompanying warrants have an initial exercise price of $1.21 per share, subject to adjustment following a specified regulatory milestone, are immediately exercisable from the date of issuance and will expire five years from the date of issuance.

GlobeNewsWire

PMV Pharma Announces Proposed Public Offering of Securities

PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, in lieu of common stock, to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchase shares of its common stock. All of the shares, pre-funded warrants and accompanying common stock warrants to be sold in the proposed offering are to be sold by PMV Pharma. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

GlobeNewsWire

PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced updated interim ovarian cancer data from the Phase 2 pivotal portion of the PYNNACLE clinical trial. The multicenter, single-arm, registrational Phase 2 trial is assessing rezatapopt as monotherapy at a dose of 2000 mg once-daily in patients with TP53 Y220C advanced solid tumors.

GlobeNewsWire

PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?

PMV Pharmaceuticals (PMVP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

GlobeNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-12	-0.41	-0.34	0.07
2026-03-06	-0.4	-0.34	0.06
2025-11-12	-0.4	-0.4	0
2025-08-07	-0.39	-0.41	-0.02
2025-05-09	-0.37	-0.34	0.03
2025-03-03	-0.38	-0.45	-0.07
2024-11-07	-0.35	-0.37	-0.02
2024-08-08	-0.34	-0.02	0.32
2024-05-09	-0.35	-0.3	0.05
2024-02-29	-0.39	-0.31	0.08
2023-11-09	-0.45	-0.34	0.11
2023-08-09	-0.47	-0.38	0.09